[1] Westergaard ML, Munksgaard SB, Bendtsen L, Jensen RH. Medication-overuse headache:a perspective review[J]. Ther Adv Drug Saf, 2016, 7:147-158. [2] Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andrée C. The cost of headache disorders in Europe:the Eurolight project[J]. Eur J Neurol, 2012, 19:703-711. [3] Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain[J]. Cephalalgia, 1988, 8 Suppl 7:1-96. [4] Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders:2nd edition[J]. Cephalalgia, 2004, 24 Suppl 1:9-160. [5] Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition[J]. Cephalalgia, 2018, 38:1-211. [6] Moavero R, Stornelli M, Papetti L, Ursitti F, Ferilli MAN, Balestri M, Sforza G, Tarantino S, Vigevano F, Valeriani M. Medication overuse withdrawal in children and adolescents does not always improve headache:a cross-sectional study[J]. Front Neurol, 2020, 11:823. [7] Shnayder NA, Sharavii VB, Petrova MM, Moskaleva PV, Pozhilenkova EA, Kaskaeva DS, Tutynina OV, Popova TE, Garganeeva NP, Nasyrova RF. Candidate genes and proteomic biomarkers of serum and urine in medication-overuse headache[J]. Int J Mol Sci, 2021, 22:9024. [8] Russell MB. Epidemiology and management of medication-overuse headache in the general population[J]. Neurol Sci, 2019, 40(Suppl 1):23-26. [9] Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache:risk factors, pathophysiology and management[J]. Nat Rev Neurol, 2016, 12:575-583. [10] Green MW. Medication overuse headache[J]. Curr Opin Neurol, 2021, 34:378-383. [11] Salhofer-Polanyi S, Zebenholzer K, Berndl T, Kastrati K, Raab S, Schweitzer P, Stria T, Topic P, Wöber C. Medication overuse headache in 787 patients admitted for inpatient treatment over a period of 32 years[J]. Cephalalgia, 2020, 40:808-817. [12] Schwedt TJ, Buse DC, Argoff CE, Reed ML, Fanning KM, Hussar CR, Adams AM, Lipton RB. Medication overuse and headache burden:results from the CaMEO study[J]. Neurol Clin Pract, 2021, 11:216-226. [13] Diener HC, Antonaci F, Braschinsky M, Evers S, Jensen R, Lainez M, Kristoffersen ES, Tassorelli C, Ryliskiene K, Petersen JA. European Academy of Neurology guideline on the management of medication-overuse headache[J]. Eur J Neurol, 2020, 27:1102-1116. [14] Wang YF, Yu CC, Kuan AS, Chen SP, Wang SJ. Association between suicidal risks and medication-overuse headache in chronic migraine:a cross-sectional study[J]. J Headache Pain, 2021, 22:36. [15] Find NL, Terlizzi R, Munksgaard SB, Bendtsen L, Tassorelli C, Nappi G, Katsarava Z, Lainez M, Goicochea MT, Shand B, Fadic R, Spadafora S, Pagani M, Jensen R; COMOESTAS Consortium. Medication overuse headache in Europe and Latin America:general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study[J]. J Headache Pain, 2015, 17:20. [16] Ashina M. Migraine[J]. N Engl J Med, 2020, 383:1866-1876. [17] Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine:a longitudinal population-based study[J]. Headache, 2008, 48:1157-1168. [18] Saengjaroentham C, Strother LC, Dripps I, Sultan Jabir MR, Pradhan A, Goadsby PJ, Holland PR. Differential medication overuse risk of novel anti-migraine therapeutics[J]. Brain, 2020, 143:2681-2688. [19] Migliore S, Paolucci M, Quintiliani L, Altamura C, Maffi S, D'Aurizio G, Curcio G, Vernieri F. Psychopathological comorbidities and clinical variables in patients with medication overuse headache[J]. Front Hum Neurosci, 2020, 14:571035. [20] American Psychiatric Association. Diagnostic and statistical manual of mental disorders[M]. 5th ed. Washington DC:American Psychiatric Publishing, 2013:481-490. [21] Kristoffersen ES, Benth JŠ, Straand J, Russell MB, Lundqvist C. Validity of self-reported assessment of severity of dependence scale in medication:overuse headache[J]. Scand J Pain, 2019, 19:837-841. [22] Corand V, Moisset X, Radat F, Lucas C; working group. Medication overuse headache:updating of the French recommendations regarding the treatment strategies[J]. Rev Neurol (Paris), 2021, 177:760-764. [23] Evers S, Jensen R; European Federation of Neurological Societies. Treatment of medication overuse headache:guideline of the EFNS headache panel[J]. Eur J Neurol, 2011, 18:1115-1121. [24] Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, Porreca F, Silberstein S, Schwedt T. Pathophysiology, prevention, and treatment of medication overuse headache[J]. Lancet Neurol, 2019, 18:891-902. [25] Carlsen LN, Munksgaard SB, Nielsen M, Engelstoft IMS, Westergaard ML, Bendtsen L, Jensen RH. Comparison of 3 treatment strategies for medication overuse headache:a randomized clinical trial[J]. JAMA Neurol, 2020, 77:1069-1078. [26] Rouw C, Munksgaard SB, Engelstoft IMS, Nielsen M, Westergaard ML, Jensen RH, Bendtsen L, Carlsen LN. Dependence-like behaviour in patients treated for medication overuse headache:a prospective open-label randomized controlled trial[J]. Eur J Pain, 2021, 25:852-861. [27] Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P. Aids to management of headache disorders in primary care (2nd edition):on behalf of the European Headache Federation and Lifting The Burden:the Global Campaign against Headache[J]. J Headache Pain, 2019, 20:57. [28] Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD. Erenumab in chronic migraine with medication overuse:subgroup analysis of a randomized trial[J]. Neurology, 2019, 92:e2309-2320. [29] Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse:real-life effectiveness and predictors of response at 6 months[J]. J Headache Pain, 2021, 22:120. [30] Tepper SJ, Ashina M, Reuter U, Hallström Y, Broessner G, Bonner JH, Picard H, Cheng S, Chou DE, Zhang F, Klatt J, Mikol DD. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab:post-hoc analyses of episodic and chronic migraine clinical trials[J]. J Headache Pain, 2021, 22:81. [31] Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P, Pascazio A, Mascarella D, Matteo E, Quintana S, Asioli GM, Cortelli P, Pierangeli G, Guerzoni S, Cevoli S. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache[J]. Neurol Sci, 2022, 43:1273-1280. [32] Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni S. Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache:an observational, retrospective, 12-month real-life study[J]. Neurol Sci, 2021, 42:4193-4202. [33] Curone M, Tullo V, Bussone G. Effectiveness of erenumab in chronic migraine patients with associated medication overuse headache:a prospective observational study[J]. Neurol Sci, 2020, 41(Suppl 2):509-510. [34] Schiano di Cola F, Rao R, Caratozzolo S, Di Cesare M, Venturelli E, Balducci U, Sidoti V, Pari E, Costanzi C, di Summa A, Sixt GJ, D'Adda E, Liberini P, Padovani A. Erenumab efficacy in chronic migraine and medication overuse:a real-life multicentric Italian observational study[J]. Neurol Sci, 2020, 41(Suppl 2):489-490. [35] Talbot J, Stuckey R, Crawford L, Weatherby S, Mullin S. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment-real world outcomes[J]. J Headache Pain, 2021, 22:5. [36] Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J, Dong Y, Pearlman EM. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine[J]. Cephalalgia, 2021, 41:340-352. [37] Kristoffersen ES, Straand J, Russell MB, Lundqvist C. Disability, anxiety and depression in patients with medication-overuse headache in primary care:the BIMOH study[J]. Eur J Neurol, 2016, 23 Suppl 1:28-35. [38] Bottiroli S, Viana M, Sances G, Ghiotto N, Guaschino E, Galli F, Vegni E, Pazzi S, Nappi G, Tassorelli C. Psychological factors associated with failure of detoxification treatment in chronic headache associated with medication overuse[J]. Cephalalgia, 2016, 36:1356-1365. [39] Bottiroli S, Allena M, Sances G, De Icco R, Avenali M, Fadic R, Katsarava Z, Lainez MJ, Goicochea MT, Jensen RH, Nappi G, Tassorelli C; Comoestas Consortium. Changes in anxiety and depression symptoms associated to the outcome of MOH:a post-hoc analysis of the Comoestas Project[J]. Cephalalgia, 2018, 38:646-654. [40] Pijpers JA, Kies DA, van Zwet EW, Rosendaal FR, Terwindt GM. Behavioural intervention in medication overuse headache:a concealed double-blind randomised controlled trial[J]. Eur J Neurol, 2022[.Epub ahead of print] |